Top Three Stocks In Which Investors Lost Money

Posted by Kristi Scott November 4, 2013 0 Comment 1100 views

NQ Mobile Inc. (ADR) (NYSE:NQ) say analysts like Muddy Waters’ Carson Block; will be delisted by the end of the year. NQ Mobile is very similar to China Media Express, which in 2011 saw a short-term gain before it was targeted. NQs revenues, consider analysts like him is fake to nearly 90%.  When Muddy Waters researched about NQ Mobile, it has found that the company did not show any offices for major customer of the company like Yidaton. Incidentally, Muddy Waters considers this to be a shell company for most of NQs activities. Though, the CEO of NQ- Omar Khan too make a public appearance via Bloomberg TV, where Block had voice his opinion, the damage was too little too late. NQ Mobile simply slipped by 11.25%.

Stereotaxis, Inc. (NASDAQ:STXS) following the announcement of its Q3 results has seen prices drop by nearly 8.92%., closing at $3.98. With a market cap of 63.39million and volume trade of 997.76K, the company only had negative EPS to show for this quarter, trigger sharp decline. Though pharma companies have been doing well at the markets, STXS, a US-based healthcare firm focused on medical appliances and equipment sector failed to move upward faster on the browsers. The losses indicate that this once favoured company as the next surgical company is in deep trouble, dropping out of investor scope.

Merrimack Pharmaceuticals (NASDAQ:MACK) should have expected the fall in prices. The pharma company announced the top-line data for one its ovarian cancer drugs, indicating the results were a failure. The company has a core network biology platform around which ERBb3 antibody MM121 for platinum-resistant ovarian cancer was developed. Considering that MM121 biomarkers have been successful with ovarian cancer subgroups, much was expected from this drug. However, the top-line data have been a true disappointment not only for thousands of patients look for better treatment but to investors as well who expected to gain from the new drug!

About Kristi Scott

Kristi Scott joined GDP Insider in 2005 as a Wall Street reporter for the Business and Market section. Kristi covers the stock market, financial markets and personal finance. Her awards have come from the National Federation of Professional Writers, the Ohio Newspaper Association, the Cleveland Press Club, the Society of Professional Journalists and Suburban Newspapers of America. Kristi was named SNA's national Journalist of the Year

View all post by Kristi Scott Visit author's website

Write Your Comment